ՄѪ֢֮֬ʳˎί
壺 С
ʱ䣺2006-09-18 00:02:40
ˎ
ǰ
Ѫ֢֬(hyperlipidemia)ѪҺe֬^ߣҪָ֬^֢(hypertriglycemia)đ̴^(hypercholesterolemia)Rԇ@ʾͿđ̴(TC)cܶ֬đ̴(LDL-C)߸ܶ֬đ̴(HDL-C)_ɽڠ}(Ľgʹļ)İlʡ
Ѫ֢֮֬ʳ
_ʼˎίǰ36£ʩʳ(ίѪ֢֮֬һ)ʳNxϣcʾ
1.֬ţ̕rxÓ̻֬֬ţ̣rx⡣
2.pđ̴֮zȡԺđ̴^ߵʳ(K..ĵ)
3.оָʳ^Խ͵ܶđ̴(LDL-C)KнѪЧʳá
4.zȡ֬{rͿúSԪ֬(ϙͻ)Ɏ͵ܶđ̴(LDL-C)đ̴(TC)
Ѫ֢֮֬ˎί
ΪʳԿѪ֬|tɼˎρί併Ѫ֬ÙCDɷ飺
1đՄ(Bileacidsequestrants)
ˎcđYԜpcѭhеãʹμđ̴ϳđ֮ʼӿ죬pđ̴ЧɽLDL-C15~30HDL-C3~5Ҫ֮Þcθm(縹Û)춴ˎxӽQ֬ˎpˎ֮գgڽo֬֬ˎǰ1Сr4СrͶc籾Ժ֮`F洼`Cholestyramine(Questran)ǰãʹǰҺwС
2|(Nicotinicacid)
ƸKڵף˿ɽTCLDL-C֬(TG)KHDL-C|ίѪ֢֬ĵһˎ횴1~3g˕rҵijtɦW׳F
3wS(Fibricacidderivatives)
ҪƸKϳLDL-CTGҪÁTG
籾Ժ֮`Z`Fenofibrate(200mg)ÿ1丱Þcθmιָٔ˳FƤȣͣˎ֢ʧʹÿѪ֮߷ñˎrСģ{Ѫ֮
4HMG-COA߀ԭÊƄ
ˎƸKϳđ̴ʛQE֮أpđ̴֮ϳɣʹѪTCLDL-CȽ͡^ʹʹ^Ҋ֮ãͨʹһΕrg͕ʧżlιָӡⲡ׃MyܽȆ}˕rͣˎ̎籾Ժ֮Atorvastatin(Lipitor)併LDL-CЧ^ҿIܓp֮ߣ^ٽIK
5Neomycin
һNw֮أ֮÷ʽcđ֭ڵđ̴Yϣ֬ᣬđ̴đ׃θcоNķցѡ
YՓ
Aίƽrܔzȡ⡢֬ʳƁKm\ԾSwأґעɳC֮ѪΣUӣ䟟ѪѪǵĿƣAѪ֢֬İl
Yϣ
PrinciplesofMedicalPharmacology
tW297
wˎWp.272~282
ˎWsI66p.168p.13671p.50
鿴